What Is the Difference Between Pharmaceutical Intermediates and APIs?
2026-07-13
1. How Do Intermediates Differ From APIs in Chemical Structure and Purpose?
In our factory, we manufacture a wide range of chemical compounds for global pharmaceutical companies. The fundamental difference between an Intermediate and an API is that the Intermediate is a chemical building block, whereas the API is the final active molecule that produces the therapeutic effect. An Intermediate may undergo several more chemical transformations – such as oxidation, reduction, or esterification – before it becomes the API. For example, a simple ketone used as an Intermediate is not intended to interact with biological targets; its sole purpose is to serve as a precursor. At Sandoo, we produce over 50 types of Intermediates, each with specified purity and impurity profiles. One of our most common Intermediates is used to synthesize a popular statin drug. This Intermediate has a purity of 98 percent, while the final API must achieve 99.5 percent or higher. The chemical structure of the Intermediate is simpler and typically lacks the final functional groups that confer pharmacological activity.
2. What Are the Regulatory Differences Between Intermediates and APIs?
Regulatory oversight is one of the clearest distinctions. APIs must be manufactured under current Good Manufacturing Practice (cGMP) and are subject to stringent quality controls by agencies like the FDA, EMA, and PMDA. They require a Drug Master File (DMF) and are audited on a regular basis. Intermediates, while still requiring quality control, are not held to the same level of scrutiny. Our factory produces Intermediates under ISO 9001 and follows cGMP guidelines, but we do not need to file a DMF for each Intermediate unless the customer specifically requests it. For the export of Intermediates to the US or Europe, we provide a Certificate of Analysis and a detailed impurity profile, but we do not need to register the product with the authorities. This reduced regulatory burden makes Intermediates faster to market and more cost effective. However, when our Intermediates are further processed into APIs by our clients, those final products must undergo full regulatory evaluation. At Sandoo, we ensure that our Intermediates are traceable and documented to support our customers' regulatory submissions.
3. What Are the Typical Purity and Specification Requirements for Intermediates?
The specifications for Intermediates are driven by the downstream synthesis process. An Intermediate does not need to meet the ultra high purity of an API, but it must be consistent to ensure reproducible yields in the next steps. Our factory sets typical purity targets between 95 and 99 percent for Intermediates, depending on the molecule. The table below outlines the general specification ranges we use for our standard Intermediates.
| Parameter | Intermediate (our typical specification) | API (typical requirement) |
| Purity (HPLC, area %) | 95 – 99% | ≥ 99.5% |
| Maximum single impurity | ≤ 1.5% | ≤ 0.15% |
| Maximum total impurities | ≤ 3.0% | ≤ 0.5% |
| Residual solvents (ICH class 2) | ≤ 1000 ppm | ≤ 300 ppm |
| Heavy metals (as Pb) | ≤ 20 ppm | ≤ 10 ppm |
| Characteristic | Intermediate | API |
| Regulatory filing required | No (DMF usually not needed) | Yes (DMF, NDA, or ANDA) |
| cGMP audit scope | Less stringent (ISO 9001 + cGMP guidelines) | Full cGMP compliance |
| Stability study requirement | Limited (usually 6 months) | Comprehensive (12 – 36 months) |
| Biological activity | None (not intended for human use) | Active therapeutic effect |
| Packaging & labeling requirements | Standard chemical packaging | Special packaging with tamper evidence |
Our factory uses high performance liquid chromatography (HPLC) and gas chromatography (GC) to test every batch of Intermediates. We also provide a 12 month retest period for our Intermediates, which is shorter than the 36 month shelf life typical for APIs. The lower purity and broader impurity limits reflect the fact that Intermediates will undergo further purification in subsequent synthetic steps.
4. How Does the Cost Structure Differ Between Intermediates and APIs?
Cost is a major factor in the supply chain. Intermediates are generally less expensive to produce than APIs because they involve fewer synthetic steps, lower purity requirements, and less regulatory documentation. Our factory produces Intermediates in large volumes, often in multi ton batches, which drives down the unit cost. For instance, a key Intermediate for an antihypertensive drug might cost 150 USD per kilogram, while the final API could cost over 2,000 USD per kilogram. This cost difference arises from the additional purification, chiral resolution, and stringent quality testing required for the API. By outsourcing the production of Intermediates to us, pharmaceutical companies can focus their resources on the final API synthesis and formulation. Our Sandoo Pharmaceuticals and Chemicals Co.,Ltd. has optimized our processes to offer Intermediates at competitive prices without compromising on consistency. We also offer long term supply agreements that stabilize pricing for our clients. Many generic drug manufacturers rely on our Intermediates to keep their overall production costs manageable.
Frequently Asked Questions About Pharmaceutical Intermediates and APIs
Final Summary
Understanding the difference between pharmaceutical Intermediates and APIs is essential for anyone involved in drug development or manufacturing. Intermediates are chemical precursors that require further synthesis; they have lower purity requirements and fewer regulatory burdens. APIs are the final active ingredients with rigorous quality and safety standards. Our factory specializes in producing high quality Intermediates that meet global specifications. We support your supply chain with consistent quality, reliable documentation, and competitive pricing. Our Sandoo Pharmaceuticals and Chemicals Co.,Ltd. is your partner from molecule to medicine.